These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 18049890)

  • 21. CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial.
    Leyland-Jones B; Gray KP; Abramovitz M; Bouzyk M; Young B; Long B; Kammler R; Dell'Orto P; Biasi MO; Thürlimann B; Lyng MB; Ditzel HJ; Harvey VJ; Neven P; Treilleux I; Rasmussen BB; Maibach R; Price KN; Coates AS; Goldhirsch A; Pagani O; Viale G; Rae JM; Regan MM
    Breast Cancer Res Treat; 2015 Jun; 151(2):373-84. PubMed ID: 25935582
    [TBL] [Abstract][Full Text] [Related]  

  • 22. FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer.
    Thussbas C; Nahrig J; Streit S; Bange J; Kriner M; Kates R; Ulm K; Kiechle M; Hoefler H; Ullrich A; Harbeck N
    J Clin Oncol; 2006 Aug; 24(23):3747-55. PubMed ID: 16822847
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Poor-prognosis estrogen receptor-positive breast cancer identified by histopathologic subclassification.
    Webster LR; Lee SF; Ringland C; Morey AL; Hanby AM; Morgan G; Byth K; Mote PA; Provan PJ; Ellis IO; Green AR; Lamoury G; Ravdin P; Clarke CL; Ward RL; Balleine RL; Hawkins NJ
    Clin Cancer Res; 2008 Oct; 14(20):6625-33. PubMed ID: 18927304
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Correlation of nm23-H1 gene expression with clinical outcome in patients with advanced breast cancer.
    Sgouros J; Galani E; Gonos E; Moutsatsou P; Belechri M; Skarlos D; Dionyssiou-Asteriou A
    In Vivo; 2007; 21(3):519-22. PubMed ID: 17591363
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genetic variation in the androgen estrogen conversion pathway in relation to breast cancer prognosticators.
    Darabi H; Czene K; Wedrén S; Li Y; Liu J; Hall P; Humphreys K
    Breast Cancer Res Treat; 2011 Jun; 127(2):503-9. PubMed ID: 20960227
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vascular endothelial growth factor polymorphisms in relation to breast cancer development and prognosis.
    Jin Q; Hemminki K; Enquist K; Lenner P; Grzybowska E; Klaes R; Henriksson R; Chen B; Pamula J; Pekala W; Zientek H; Rogozinska-Szczepka J; Utracka-Hutka B; Hallmans G; Försti A
    Clin Cancer Res; 2005 May; 11(10):3647-53. PubMed ID: 15897560
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genetic polymorphisms in the MMP-2 and MMP-9 genes and breast cancer phenotype.
    Grieu F; Li WQ; Iacopetta B
    Breast Cancer Res Treat; 2004 Dec; 88(3):197-204. PubMed ID: 15609121
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association of interleukin-10 gene variation with breast cancer prognosis.
    Gerger A; Renner W; Langsenlehner T; Hofmann G; Knechtel G; Szkandera J; Samonigg H; Krippl P; Langsenlehner U
    Breast Cancer Res Treat; 2010 Feb; 119(3):701-5. PubMed ID: 19437115
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HER2/neu expression in relation to clinicopathologic features of breast cancer patients.
    Traina A; Agostara B; Marasà L; Calabrò M; Zarcone M; Carruba G
    Ann N Y Acad Sci; 2006 Nov; 1089():159-67. PubMed ID: 17261764
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The CYP19 TTTA repeat polymorphism is related to the prognosis of premenopausal stage I-II and operable stage III breast cancers.
    Huang CS; Kuo SH; Lien HC; Yang SY; You SL; Shen CY; Lin CH; Lu YS; Chang KJ
    Oncologist; 2008 Jul; 13(7):751-60. PubMed ID: 18614591
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression of KLF5 is a prognostic factor for disease-free survival and overall survival in patients with breast cancer.
    Tong D; Czerwenka K; Heinze G; Ryffel M; Schuster E; Witt A; Leodolter S; Zeillinger R
    Clin Cancer Res; 2006 Apr; 12(8):2442-8. PubMed ID: 16638850
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association between DNA damage, DNA repair genes variability and clinical characteristics in breast cancer patients.
    Synowiec E; Stefanska J; Morawiec Z; Blasiak J; Wozniak K
    Mutat Res; 2008 Dec; 648(1-2):65-72. PubMed ID: 18977234
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Polymorphisms in telomere-associated genes, breast cancer susceptibility and prognosis.
    Varadi V; Brendle A; Brandt A; Johansson R; Enquist K; Henriksson R; Svenson U; Tavelin B; Roos G; Hemminki K; Lenner P; Försti A
    Eur J Cancer; 2009 Nov; 45(17):3008-16. PubMed ID: 19766477
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quantitative determination, by real-time reverse transcription polymerase chain reaction, of aromatase mRNA in invasive ductal carcinoma of the breast.
    Zhang Z; Yamashita H; Toyama T; Omoto Y; Sugiura H; Hara Y; Wu X; Kobayashi S; Iwase H
    Breast Cancer Res; 2003; 5(6):R250-6. PubMed ID: 14580261
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Breast cancer patients with p53 Pro72 homozygous genotype have a poorer survival.
    Tommiska J; Eerola H; Heinonen M; Salonen L; Kaare M; Tallila J; Ristimäki A; von Smitten K; Aittomäki K; Heikkilä P; Blomqvist C; Nevanlinna H
    Clin Cancer Res; 2005 Jul; 11(14):5098-103. PubMed ID: 16033823
    [TBL] [Abstract][Full Text] [Related]  

  • 36. LFA-1 gene polymorphisms are associated with the sporadic infiltrative duct breast carcinoma in Chinese Han women of Heilongjiang Province.
    Fu Z; Jiao M; Zhang M; Xu F; Yuan W; Pang D; Li D
    Breast Cancer Res Treat; 2011 May; 127(1):265-71. PubMed ID: 20953905
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Is triple negative a prognostic factor in breast cancer?
    Nishimura R; Arima N
    Breast Cancer; 2008; 15(4):303-8. PubMed ID: 18369692
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A comparative assessment of HER2 status in operable breast cancer by real-time RT-PCR and by immunohistochemistry.
    Potemski P; Płuciennik E; Bednarek AK; Kusińska R; Pasz-Walczak G; Jesionek-Kupnicka D; Watala C; Kordek R
    Med Sci Monit; 2006 Dec; 12(12):MT57-61. PubMed ID: 17136015
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Allelic imbalance of HER-2 codon 655 polymorphism among different religious/ethnic populations of northern Greece and its association with the development and the malignant phenotype of breast cancer.
    Papadopoulou E; Simopoulos K; Tripsianis G; Tentes I; Anagnostopoulos K; Sivridis E; Galazios G; Kortsaris A
    Neoplasma; 2007; 54(5):365-73. PubMed ID: 17918664
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifen.
    Kok M; Linn SC; Van Laar RK; Jansen MP; van den Berg TM; Delahaye LJ; Glas AM; Peterse JL; Hauptmann M; Foekens JA; Klijn JG; Wessels LF; Van't Veer LJ; Berns EM
    Breast Cancer Res Treat; 2009 Jan; 113(2):275-83. PubMed ID: 18311582
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.